AUAUniversity American Urological Association
-
- Education
-
The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
-
AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management
AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management
CME Available: https://auau.auanet.org/node/41040
At the conclusion of this activity, participants will be able to:
1. Identify clinically available data that can help assess risk of UTUC disease.
2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.
3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.
4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.
5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.
ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck & Co., Inc., UroGen Pharma, Inc. -
AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider
AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider
CME Available: https://auau.auanet.org/node/41048
At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.
3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents
5. Discuss potential future pharmacological pathways and therapies for OAB.
ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas -
AUA2024: Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder
Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)
CME Available: https://auau.auanet.org/node/41056
At the conclusion of this activity, participants will be able to:
1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques.
2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients.
3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device.
4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB.
5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit.
ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas -
AUA2024: Genetics and Genomics of Urological Cancers
AUA2024: 003IC Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice
CME Available: https://auau.auanet.org/node/40976
At the conclusion of this activity, participants will be able to:
1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.
2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.
3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.
4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.
ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. -
Journal Club 101
Journal Club 101
Guest: Melissa Kaufman, MD, PHD, FACS
Outline:
Segment #1: History of peer review
Segment #2: Models of peer review
Segment #3: General review best practices
Segment #4: General structure for manuscript review
Segment #5: Granular aspects of manuscript review -
BPH: Surgical Treatment
BPH: Surgical Treatment
Guest: Bilal Chughtai, MD
Outline:
Segment #1: Bladder Health
Segment #2: Diagnostics
Segment #3: Stents
Segment #4: New MISTs
Customer Reviews
Very good content, music is not nice
Please get rid of music in beginning and end. It’s difficult to hear the speakers over it. Also some audio quality is not good.
Content is excellent from world experts
Very good content, but please fix the audio component so that I can actually hear the podcast
Excellent series on GU malignancies at the end of 2020. Please please please fix the audio to make it legible.
Thank you
Perfect for my long drives to a satellite hospital.